Infectious Bursal Disease Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

Infectious Bursal Disease Vaccine Market

The future of the global infectious bursal disease vaccine market looks promising with opportunities in the veterinary pharmacy and online sale markets. The global infectious bursal disease vaccine market is expected to reach an estimated $709 million by 2035 from $389 million in 2027 with a CAGR of 5.2% from 2027 to 2035. The major drivers for this market are the rising poultry production and the outbreaks of infectious bursal disease.

• Lucintel forecasts that, within the type category, live is expected to witness higher growth over the forecast period due to rising demand for rapid and long-lasting immunity in poultry flocks is boosting the adoption of live vaccines.
• Within the application category, online sale is expected to witness the higher growth due to rising demand for convenient procurement is driving poultry farmers to purchase IBD vaccines online, offering ease of access and timely delivery.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the developing industry of large scale commercial poultry farming and strong veterinary supply chains.

Emerging Trends in Infectious Bursal Disease Vaccine Market

Between 2025 and 2027 the infectious bursal disease vaccine market will shift from routine vaccination towards region-specific, higher efficacy programs. Poultry integrators require stronger field control and improved flock performance with greater flexibility in the timing and form of delivery. According to Lucintel, innovation, biosecurity, and on-farm flexibility will be the key competitive factors in both established and up-and-coming poultry regions.

• Next-Generation Live Vaccines: Intermediate-Plus and Immune-Complex vaccines are gaining popularity in situations where standard vaccines may be inhibited by maternal antibodies; field programs during 2025-2027 incorporate lab-based titration and will include frequent farm-level monitoring. Control of maternal antibody levels is key for the next 3 to 5 years as integrators seek protection with minimal bursal damage.
• Vector and Recombinant Platforms: Host Vector Technology and Recombinant Platforms, including vaccines addressing IBD and other poultry pathogens, are being developed by several suppliers; protective programs are targeting hatchery vaccination. Innovation in these platforms may be the driver of market growth as integrated vaccination programs require fewer handling steps to achieve consistency.
• Precision Vaccination: Hatchery vaccinators and spray equipment, along with digital vaccination records and automated systems, have pushed vaccination away from fixed intervals; the large operations adjust, based on maternal-antibody testing and mortality data. In the next 5 years, precision vaccination will achieve improved vaccine take, improved flock outcomes and significantly reduce labor requirements.
• Region-Specific Strain Matching: Producer reports of significant differences in the challenge of very virulent IBDV in Asia, the Middle East, Latin America, and Africa, are resulting in the use of locally sourced, validated strains and challenge-specific control programs. This trend will continue to drive the need for differentiated product offerings as the challenge specific programs will incorporate multiple control strategies.
• Integrated Disease Management: WOAH and national poultry authorities continue to integrate vaccination with biosecurity, diagnostics, and surveillance. In 2025, producers began to see IBD control as a whole-farm challenge rather than an isolated purchase. With this as a service-dose offering, suppliers will have a competitive advantage in the market.

Companies will have to rely more on field evidence, hatchery and regional support than product registrations to compete. Manufacturers that can supply diagnostics along with a stable supply will gain the confidence of large integrators. Smaller producers will be price driven and vaccine adoption will remain strong in the high growth poultry markets until 2030.

Recent Developments in the Infectious Bursal Disease Vaccine Market

The market for infectious bursal disease vaccines will continue to move away from conventional live vaccines towards more sophisticated recombinant, immune complex and vector vaccine platforms. This market growth is primarily attributed to constant demands from poultry integrators for greater flock protection, especially through 2027. Lucintel projects that investments will be primarily driven by regional disease pressure, the requirements for more robust biosecurity, and greater production efficiency in broiler operations.

• Vector Vaccines: In 2025, Boehringer Ingelheim completed new registrations of VAXXITEK HVT+IBD, thus reinforcing the use of vector vaccines as a legitimate alternative to repeated live vaccinations. With the support of vector vaccines, complexity of vaccination administration should lessen over the next 3-5 years as a new premium segment of the market is created.
• IBD Vaccine Approvals: The regulatory environment in China continued to support locally manufactured IBD vaccines in 2025 by new approvals of veterinary biological products. It is expected that an even faster pace of domestic approvals will lead to greater competition in the region, the largest poultry market, and reduced reliance on imported vaccines.
• Poultry Vaccine Demand: In 2025, Indian manufacturers increased capacities for production of poultry biologicals to meet greater demand by the broiler sector which will likely grow to over 5 billion birds annually. New additional capacity will enhance the market's flexibility, which will exert demand on the existing multinational suppliers.
• Research Collaborations: In 2025, vaccine manufacturers and integrators joined forced to conduct field studies with immune complex products under commercial conditions in order to gain competitive advantage. In this market, performance on the farms is now a major factor in purchasing decisions, especially when live vaccine efficacy is variable due to maternal antibodies.
• Portfolio Acquisitions: Continues to be a theme for animal-health companies during 2025 with acquisitions to enhance their poultry vaccine offerings beyond the scope of their existing portfolio. Medium term acquisitions of regional distributors or niche manufacturers can provide market access, strengthen the cold chain, and consolidate partially integrated distributions.

The next phase of the market will be characterized by a shift from a volume-centric market to a market that is more concerned with consistency of protection and the convenience of application along with regulatory approvals. The next phase of the market will see integrators prioritizing products that may be more expensive up front but result in lower losses. Price sensitive markets will remain committed to traditional live products, but supplier differentiation will become a greater concern for consistent, reliable regional manufacturing, technical service, and field data.

Strategic Growth Opportunities in the Infectious Bursal Disease Vaccine Market

Demand for infectious bursal disease (IBD) vaccines from 2024 to 2026 will shift from routine prevention to demand for tailored vaccines for strain-specific outbreak control. Growing domestic poultry production and more relentless use of antibiotics, along with the uneven field immunity, will create additional business opportunities. According to Lucintel, other business opportunities may come from differentiated biologics, regional production, and service offerings based on the performance of the vaccines.

• Strain-matched Vaccines: From March 2025, it is estimated that vaccine sales from variants of IBDV in Brazil will have almost doubled, where it was recorded that there were approximately 15.3 billion chickens. It is expected that better matching of antigens will result in increased sales prices and reduced economic losses from breaking the immunity of the birds in approximately the next 3 to 5 years.
• In-ovo and Hatchery Vaccines: In January 2025, the majority of the large hatcheries continued to automate the delivery of vaccines. The first delivery of vaccines will ensure that the integrators will extend their contracts to the hatchery since it will provide greater coverage with less labor, and better control of the schedule of the birds in the flock.
• Expanding To New Markets: In June 2025, India had an estimated total poultry population of about 800 million. New registrations, building partnerships with distributors, and having local production may allow vaccines for poultry to be more available and used in the increasing number of African and South Asian countries where there are ample gaps in the intensity of poultry vaccinations.
• Digital Flock Monitoring: Some producers in Europe started recording performances and mortality of chickens in flocks from cloud-based systems in February 2025. Providing this service will improve existing sources of income since revenue will be generated from contracts for providing the needed technical services and loss-monitoring support.
• Premium Low-temperature Formulations: Refrigerated transport was reported to operate between 2°C and 8°C in April 2025. New formulations and improved packaging will reduce losses from spoilage and help provide services in remote markets where failure to maintain a cold chain is common.

In the next five years, winners will no longer rely solely on dose volume. They will combine strain coverage, reliable cold chains, evidence from commercial flocks, and timely technical support. Producers are now purchasing reduced risk over a vial. Suppliers that produce closer to the customer, document the results, and serve integrators directly will gain the strongest margin growth for the global infectious bursal disease vaccine market.

Infectious Bursal Disease Vaccine Market Drivers and Challenges

Market growth of the infectious bursal disease (IBD) vaccine is highly dependent on poultry farming, disease levels, biotechnology, regulation, and farm economics. Rising demand for protein draws vaccination demand, while evolving strains drive the need for new formulations. Adoption is also impacted by the manufacture capacity and the availability of cold chains. Major impediments remain in veterinary regulation and infrastructure and price sensitivity. Lucintel has identified disease prevention, productivity protection, and innovation as the leading drivers of competitive market development.

The factors responsible for driving this market include :

• Customer Demand: Increasing consumption of poultry prompts producers to protect their flocks to maintain a consistent supply. In 2025, global production of poultry meat exceeded 140 million metric tons and sustained the demand for preventive vaccines. There is an expectation that, over the next three to five years, population growth, urbanization, and the demand for low-cost animal protein will spur vaccination in all of Asia, Latin America, and Africa. There is a shift in perception from considering vaccinations as a veterinary expense to an important productivity expenditure.
• Technology: There are new and improved vaccine technologies-recombinant, vector-based, immune-complex, thermostable vaccines, etc.-that improve coverage against various IBD strains. During 2025, many commercial vaccination programs generally used single-dose or multiple-dose formats based on the level of maternal antibodies. Protection Precision(TM) will improve antigen selection, molecular surveillance, and digital flock monitoring in the next three to five years to enable vaccine efficacy breeding, narrow immune gaps and improve adoption for high-density poultry.
• Regulatory Support: Governments and veterinary services promote loss mitigation and protection of national poultry supplies by supporting vaccination, biosecurity, and surveillance of animal disease. In 2025, several programs in the regulated poultry sector required vaccination and Traceability of commercial poultry flocks. Pacing documentation of this vaccination requirement will sustain compliance demand in the years to come. It is expected that, in the next three to five years, the openness to approve vaccines and set higher standards for disease control will generate new markets. Although national differences in requirements may affect the timing of the new vaccines and increase the cost of registration for manufacturers.
• Sustainability: Vaccination reduces mortality and improves feed to gain ratio, resulting in less feed required and less waste of resources. In September 2025, more poultry producers integrated preventive health programs and set objectives to reduce environmental impact in terms of resources consumed in the production of meat and eggs. In the next three to five years, sustainability reports and goals to further reduce the use of antibiotics and carbon emissions will stimulate the use of vaccines in integrated poultry farm management, as long as feed and energy costs are high.
• Manufacturing Efficiency: Regional manufacturing, increased capacity, and control of production will lower unit cost and improve supply reliability. In April 2025, many commercial vaccine production facilities adopted procedures to test batches and maintain the cold chain of vaccine products during the production and transportation process. Automation, increased local capacity for fill-and-finish, and better supply chain forecasting will reduce shortages and improve delivery of advanced infectious bursal disease vaccines for small and medium poultry producers.

The challenges facing this market include:

• Incomplete Protection Due To Changing Viruses: Infectious Bursal Disease viruses are continuously evolving, and antigenic changes in the circulating strain may lead to reduced protection for poultry. During 2025 field vaccination campaigns, most of the programs implemented booster or adjusted vaccination schedules due to maternal antibodies and strain pressures resulting in uncertain immunity. Unsolved viral changes will lead to a greater need for continuous surveillance and rapid diagnostics in the next 3-5 years, increase Formulation changes and research, leading to greater costs and extending standard and planned vaccination schedules across international boundaries.
• Regulatory and Supply Issues: There are long waits for approvals for safety concerns and logistical supply chain issues requiring refrigeration and veterinary oversight. In July 2025, many rural poultry operations relied on unstable and risky cold-chain systems. Over the next 3-5 years, market penetration will be slow due to the sustained regulatory, border and infrastructure gaps across developing countries. In these countries, exposure to poultry disease is high, but distribution networks remain unavailable.
• Price and Adoption: Small and medium-sized poultry companies may delay implementation of vaccination schedules if the price becomes too high for them. During March of 2025, vaccination programs across farms required at least one well-timed dose, while many farms opted to use more than one dose depending on the risk factors present. In the next 3-5 years, unpredictable inflation and price volatility will encourage under-vaccination of poultry which will negatively affect producers and ultimately reduce demand stability.

As production and prevention of economically-relevant diseases becomes a concern for poultry producers, the market for infectious bursal disease vaccines will show increased growth due to more advanced vaccine technology. There will be more sustainability goals, better manufacture efficiency, less wastage, and increased utility of resources, encouraging adoption. Variability of viruses, regulatory hurdles, the cold chain, and affordability at the farm level will constrain growth in the developing world. The leaders of this market who develop flexible vaccines in a cost effective manner that can easily reach the end users will gain more market share. The biggest investments will be in the surveillance systems, biotechnology, local vaccine production, and teaching the producers about the value of vaccines. The greatest success will be seen in the correlation of the greatest need for disease control and sustainability of market growth.

List of Infectious Bursal Disease Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies infectious bursal disease vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the infectious bursal disease vaccine market companies profiled in this report include-

• Zoetis
• Merck
• Elanco
• Boehringer Ingelheim
• Ceva
• Qingdao Yibang Biological Engineering

Infectious Bursal Disease Vaccine Market by Segment

The study includes a forecast for the global infectious bursal disease vaccine market by type, application, and region.

Infectious Bursal Disease Vaccine Market by Type [Value ($B) from 2019 to 2035]:

• Live
• Inactivated

Infectious Bursal Disease Vaccine Market by Application [Value ($B) from 2019 to 2035]:

• Veterinary Pharmacy
• Online Sale
• Others

Infectious Bursal Disease Vaccine Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Infectious Bursal Disease Vaccine Market

Activities in the market for infectious bursal disease vaccines are increasingly driven by trends in regulation, local production, and technology. From 2025 to 2027, vaccine producers are most interested in recombinant and immune-complex platforms, while governments are introducing more stringent control systems for diseases and quality systems for vaccines. According to the latest analysis by Lucintel, these changes are not expected to significantly impact the demand for traditional live vaccines.

• United States: Regulatory consistency and domestic capacity for biologics are of principal concern. In January 2025, the USDA APHIS reported more than 100 licensed veterinary biologics facilities, a vast network that will enhance the development and production of veterinary biologics, including vaccines against infectious bursal disease. This network will shorten the time needed to produce these vaccines domestically and enhance the security of the vaccine supply for the next 3 to 5 years.
• China: Local poultry disease control programs and vaccine manufacturing have the support of the government. In March 2025, the Ministry of Agriculture and Rural Affairs in China required the quality and the batch release of veterinary biologics for poultry vaccines. This will support manufacturers that are able to provide field efficacy and large-scale poultry vaccine manufacturing that is compliant with the requirements.
• Germany: Germany is the primary site for pan-European production and regulation of poultry biologics. In February 2025, Boehringer Ingelheim continued operating one of its more important veterinary biologics production facilities in Hanover, Germany. Continued production of biologics vaccines will provide advanced poultry vaccines for the region and address the need for contract manufacturing.
• India: Public and private investments are helping to develop India's own poultry vaccines. In April 2025, India's Department of Animal Husbandry and Dairying continued the implementation of the National Animal Disease Control Program during which the health of farms and the system for vaccinations of poultry will be developed. Until now, local production of vaccines against infectious bursal disease were lacking to be properly registered, distributed and used and this situation is now changing.
• Japan: Japan is strengthening biosecurity and controlled vaccine use within its national animal-health administration. In May 2025, the Ministry of Agriculture, Forestry and Fisheries maintained the approval and quality-control procedures for veterinary vaccines in the Pharmaceutical and Medical Devices policy. This will allow vaccine suppliers to strengthen the cold chain and provide better documentation and post-market surveillance.

Features of the Global Infectious Bursal Disease Vaccine Market

• Market Size Estimates: infectious bursal disease vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: infectious bursal disease vaccine market size by type, application, and region in terms of value ($B).
• Regional Analysis: infectious bursal disease vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the infectious bursal disease vaccine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the infectious bursal disease vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the infectious bursal disease vaccine market by type (live and inactivated), application (veterinary pharmacy, online sale, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?